Kebede A. Beyene

Dr. Kebede A. Beyene

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in American Journal of Public Health
Verified
Journal Article
Closed access
KBKebede A. Beyene
Kebede A. Beyene
JSJanie Sheridan
Janie Sheridan
TATrudi Aspden
Trudi Aspden
We reviewed the literature on nonrecreational prescription medication sharing. We searched PubMed, EMBASE, PsycINFO, and a customized multidatabase for all relevant articles published through 2013; our final sample comprised 19 studies from 9 countries with 36 182 participants, ranging in age from children to older adults, and published between 1990 and 2011. The prevalence rate for borrowing someone’s prescription medication was 5% to 51.9% and for lending prescription medication to someone else was 6% to 22.9%. A wide range of medicines were shared between family members, friends, and acquaintances. Sharing of many classes of prescription medication was common. Further research should explore why people share, how they decide to lend or borrow, whether they are aware of the risks, and how they assess the relevance of those risks.

3 August 2009 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
KBKebede A. Beyene
Kebede A. Beyene
TGTeferi Gedif
Teferi Gedif
TGTsige Gebre‐Mariam
Tsige Gebre‐Mariam
EEEphrem Engidawork
Ephrem Engidawork

18 August 2020 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
KBKebede A. Beyene
Kebede A. Beyene
ACAmy Hai Yan Chan
Amy Hai Yan Chan
NBNaga Sai Trisha Bandreddi
Naga Sai Trisha Bandreddi
RTReihaneh Bassam Tabar
Reihaneh Bassam Tabar
EMEmily Moyle
Emily Moyle
JHJeff Harrison
Jeff Harrison

9 September 2016 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
PDF file
KBKebede A. Beyene
Kebede A. Beyene
TATrudi Aspden
Trudi Aspden
JSJanie Sheridan
Janie Sheridan
Prescription medicine sharing has been defined as the lending of medicines (giving prescription medicines to someone else) or borrowing of medicines (being given and using a medicine prescribed for another person). This qualitative study explored the views of patients, to elicit information regarding factors influencing medicine sharing behaviours, their experiences of the consequences of prescription medicine sharing, and their risk assessment strategies when deciding to share. One-on-one, face-to-face, semi-structured interviews were carried out in Auckland, New Zealand between September 2013 and August 2014 with 17 patients, purposively sampled to provide information from different socio-demographic backgrounds. The interviews were audio recorded, transcribed verbatim and analysed using a general inductive approach. The study received ethical approval, and all interviewees provided written informed consent. Findings were captured within five overarching themes: types of shared medicines; perceived benefits of sharing medicines; negative experiences of sharing; factors influencing sharing behaviours; and risk assessment strategies. Participants reported that sharing helped them to avoid treatment costs and the inconvenience associated with medical visits such as booking appointments. Conversely, unanticipated side effects, allergies, and taking inappropriate medicines were the main adverse consequences of sharing. Altruism, limited access to medicines/health services, sociocultural factors, and having unused prescription medicines were factors influencing sharing behaviours. Participants reported assessing the safety of sharing a medicine primarily based on symptom matching, past illness experiences, and knowledge about the medicines. This study enriches previous survey findings, by providing insight into patients' reasons for medicines sharing. Healthcare providers should consider asking their patients about any medicines they have shared and their future sharing intentions, in order to use the opportunity for discussing safer sharing practices, without promoting the behaviour. The findings are helpful for informing the development of potential interventions and targeted educational messages about safe medicine use for patients.

2 November 2014 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
AGAlexandra Gascoyne
Alexandra Gascoyne
KBKebede A. Beyene
Kebede A. Beyene
JSJoanna Stewart
Joanna Stewart
TATrudi Aspden
Trudi Aspden
JSJanie Sheridan
Janie Sheridan

2 December 2021 in Australasian Journal on Ageing
Verified
Journal Article
Open access
PDF file
GCGary Cheung
Gary Cheung
SBSharmin Bala
Sharmin Bala
MLMataroria Lyndon
Mataroria Lyndon
EMEtuini Ma'U
Etuini Ma'U
CRClaudia Rivera Rodriguez
Claudia Rivera Rodriguez
XWXaviour Walker
Xaviour Walker
Objective: To investigate the impact of New Zealand's (NZ) first wave of COVID‐19, which included a nationwide lockdown, on the health and psychosocial well‐being of Māori, Pacific Peoples and NZ Europeans in aged residential care (ARC).Methods: interRAI assessments of Māori, Pacific Peoples and NZ Europeans (aged 60 years and older) completed between 21/3/2020 and 8/6/2020 were compared with assessments of the same ethnicities during the same period in the previous year (21/3/2019 to 8/6/2019). Physical, cognitive, psychosocial and service utilisation indicators were included in the bivariate analyses.Results: A total of 538 Māori, 276 Pacific Peoples and 11,322 NZ Europeans had an interRAI assessment during the first wave of COVID‐19, while there were 549 Māori, 248 Pacific Peoples and 12,367 NZ Europeans in the comparative period. Fewer Māori reported feeling lonely (7.8% vs. 4.5%, p = 0.021), but more NZ Europeans reported severe depressive symptoms (6.9% vs. 6.3%, p = 0.028) during COVID‐19. Lower rates of hospitalisation were observed in Māori (7.4% vs. 10.9%, p = 0.046) and NZ Europeans (8.1% vs. 9.4%, p < 0.001) during COVID‐19.Conclusions: We found a lower rate of loneliness in Māori but a higher rate of depression in NZ European ARC populations during the first wave of COVID‐19. Further research, including qualitative studies with ARC staff, residents and families, and different ethnic communities, is needed to explain these ethnic group differences. Longer‐term effects from the COVID‐19 pandemic on ARC populations should also be investigated.